Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience regains Nasdaq bid price compliance, hearing cancelled

Positive Impact 3 of 5 legal/regulatory Written later

Lexaria Bioscience Corp. received a letter from Nasdaq on August 17, 2026 confirming that it has regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2). As a result, the previously requested hearing was cancelled and the company's common stock will continue to be listed and trade on The Nasdaq Capital Market, which removes the near-term risk of delisting for shareholders.

Key points

  • Nasdaq letter dated August 17, 2026 confirmed compliance with the bid price requirement in Listing Rule 5550(a)(2)
  • Previously requested hearing has been cancelled
  • Common stock will continue to be listed and trading on The Nasdaq Capital Market

The filing

CompanyLexaria Bioscience Corp. (LEXX)
Form8-K, current report
Filed with the SECAug 17, 2026, 12:37 PM ET
Accession number0001640334-26-001384

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.